Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Success stories

Cyrille Pauthenier, Abolis, from research to entrepreneurship


Cyrille Pauthenier, CEO of Abolis
Abolis, Innovation 2030 Abolis, Innovation 2030

A graduate of ENS, one of France’s most prestigious Grandes Écoles, Cyrille Pauthenier was only 26 when he launched Abolis while completing his thesis at the Institute of Systems & Synthetic Biology (University of Évry-Paris Saclay).

Step by step, with his double researcher/entrepreneur profile and the discipline and energy that go with it, Cyrille grew his innovative and potential-filled start-up. He earned numerous distinctions along the way, including winning the “Technological Potential” prize in the 2013 Genopole Young Biotech Award and being a laureate of Phase 2 of the French State’s Global Innovation Competition 2030.

In Abolis and the field of synthetic biology, Cyrille sees an alternative, more ecological and bio-based path toward industrial production. With its disruptive technology built on a foundation of genetics, mathematics and informatics, his company conceives microorganisms (yeasts, bacteria, etc.) able to produce compounds of interest in industry, food & agriculture, cosmetics, pharmacology and more.

Today, Abolis is a renowned and trusted partner for industrials. The groups Bel and Lesaffre are working by Abolis’ side within the Metapath project, financed by the Investments for the Future program, to “conceive healthier and more-natural food products.”

Having attracted the attention of a wide range of markets, Cyrille Pauthenier is launching ambitious projects for Abolis, and growing the teams and infrastructures he needs to make them real at Genopole.

With support